![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/hoth-therapeutics-and-aronnax-inc-enter-master-services-agreement-for-ht-kit-cancer-therapeutic-302223147.html
https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-joint-development-agreement-with-wise-systems-international-srl-to-utilize-artificial-intelligence-for-drug-discovery-302168103.html
https://www.prnewswire.com/news-releases/hoth-therapeutics-to-attend-ef-hutton-annual-global-conference-may-15-2024-302132803.html
https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-exercise-of-warrants-for-4-2-million-gross-proceeds-302101473.html
https://www.prnewswire.com/news-releases/hoth-therapeutics-engages-altasciences-to-perform-key-study-for-ht-kit-cancer-fighting-therapeutic-302070680.html
https://www.prnewswire.com/news-releases/hoth-therapeutics-to-attend-bio-ceo-and-investor-conference-february-26-27-2024-302060867.html
https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-it-received-fda-approval-to-expand-ht-001-clinical-trial-to-treat-severely-ill-patients-302037945.html
https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-expansion-of-fda-cleared-first-in-human-clinical-trial-for-cancer-patients-of-ht-001-at-university-of-miami-302022630.html
https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-it-has-successfully-completed-manufacturing-of-its-cancer-fighting-ht-kit-for-ind-enabling-studies-302005612.html
https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-successful-completion-of-pre-ind-meeting-with-fda-regarding-development-of-hoths-cancer-fighting-ht-kit-301987112.html